Multiple Myeloma News


Here are all the latest news articles written by The Beacon's staff.

For news articles about treatments commonly given to myeloma patients, click on these links:
bisphosphonates, KyprolisPomalyst (Imnovid), Farydak (panobinostat), Revlimid, thalidomide, Velcade, and Zometa.

For news articles about potential new myeloma treatments, click on these links:
ARRY-520 (filanesib), ACY-1215 (ricolinostat), afuresertib (GSK2110183), BT-062, daratumumab, elotuzumab, ixazomib (MLN9708),  marizomib (NPI-0052), MOR202, oprozomib, SAR650984, Treanda (bendamustine), and Zolinza (vorinostat).

For news articles about specific myeloma-related topics, click on these links:
bone disease, kidney failure, MGUS, maintenance therapy, peripheral neuropathysecondary cancer, smoldering multiple myeloma, and stem cell transplants.


[ by | Apr 7, 2015 6:43 pm | No Comment ]
Combination Of Farydak And High-Dose Kyprolis Effective In Relapsed Multiple Myeloma

The results of a small Phase 1/2 clinical trial suggest that a com­bi­na­tion of Farydak and high-dose Kyprolis is effective as a treat­ment for relapsed multiple myeloma.

Participants in the trial were heavily pretreated, having had a median of five previous myeloma ther­a­pies. More than 70 per­cent of the patients, however, had at least a partial re­sponse to the trial regi­men at the target doses established during the trial’s first phase. The estimated two-year overall survival rate among the patients was 67 percent.

A response rate of more than 70 …

Read the full story »
[ by | Mar 31, 2015 5:22 pm | 11 Comments ]
Survival Of Nonsecretory Multiple Myeloma Patients Improves Over Last Decade

Results of a recent retrospective study conducted at the Mayo Clinic in­di­cate that the survival of patients with non­se­cre­tory multiple myeloma has improved over the last decade.

Nonse­cre­tory multiple myeloma is a rare form of myeloma in which a patient’s disease cannot be diagnosed or tracked by the presence of monoclonal protein in the blood or urine.  This is not the case for most myeloma patients, who have “se­cre­tory” disease which can be tracked using lab results such as a patient’s “M-spike” or free light chain levels.

The authors of …

Read the full story »
[ by and | Mar 23, 2015 5:27 pm | 8 Comments ]
Additional Treatment To Deepen Response Prior To Transplantation May Not Improve Survival In Newly Diagnosed Multiple Myeloma

A recently published study may change the goals many myeloma special­ists use to make treatment decisions for newly diagnosed myeloma pa­tients planning on having a stem cell transplant.

The study also has potentially broader implications. Indeed, it may influ­ence ongoing debate on a fundamental controversy about how multiple myeloma, in general, should be treated.

The authors of the new study looked at data for 539 myeloma patients who failed to achieve even a partial response to their initial (induction) treat­ment regimen after diagnosis.

After their initial treatment failed, some of the …

Read the full story »
[ by | Mar 10, 2015 9:24 am | 7 Comments ]
Common Chromosomal Abnormalities Occur Less Often In African-American Than White Multiple Myeloma Patients

The results of a recently published study show that, among newly diag­nosed myeloma patients, African-Americans are less likely than white Americans to have the four most common myeloma-related chro­mo­somal ab­nor­mal­ities.

The authors of the study investigated how often the chro­mo­somal ab­nor­mal­ities t(11;14), t(4;14), del(13q), and del(17p) were present in two dif­fer­ent groups of newly diagnosed myeloma patients. One group con­sisted of African-Americans, the other of white Americans.

Each of the four ab­nor­mal­ities occurred less frequently in the African-American patients.

In addition, almost two-thirds of the African-American patients (63 per­cent) did …

Read the full story »
[ by | Mar 3, 2015 10:36 pm | 8 Comments ]
High-Dose Kyprolis Extends Progression-Free Survival Versus Velcade In Head-To-Head Relapsed Myeloma Trial

Initial results of a large, head-to-head clinical trial show that relapsed myeloma patients treated with high-dose Kyprolis and dex­a­meth­a­sone had twice the progression-free survival of relapsed patients treated with Velcade and dex­a­meth­a­sone.

Median progression-free survival in the Phase 3 trial was 18.7 months in trial participants treated with high-dose Kyprolis (carfilzomib) and dex­a­meth­a­sone (Decadron), compared to 9.4 months in patients treated with Velcade (bor­tez­o­mib) and dex­a­meth­a­sone.

The results of the so-called “ENDEAVOR” trial were announced this past Sunday evening in a press release issued …

Read the full story »
[ by | Feb 26, 2015 7:40 pm | 3 Comments ]
Farydak – Questions & Answers About The FDA Approval

The U.S. Food and Drug Administration (FDA) on Monday approved Farydak (panobinostat) for the treatment of multiple myeloma (see related Beacon news).

Since the FDA announced its decision, multiple myeloma patients, care­givers, and health care professionals have been asking a number of important questions about Farydak. This article compiles many of those questions and provides answers to them.

The information in this article is based primarily on the official, FDA-approved prescribing information for Farydak. In addition, The Beacon has received feedback in regard to …

Read the full story »